Cargando…
Cardiotoxicity of Cancer Therapeutics: Current Issues in Screening, Prevention, and Therapy
In the context of modern cancer chemotherapeutics, cancer survivors are living longer and being exposed to potential comorbidities related to non-cancer side effects of such treatments. With close monitoring of cancer patients receiving potentially cardiotoxic medical therapies, oncologists, and car...
Autores principales: | Sheppard, Richard J., Berger, Jenna, Sebag, Igal A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594741/ https://www.ncbi.nlm.nih.gov/pubmed/23487556 http://dx.doi.org/10.3389/fphar.2013.00019 |
Ejemplares similares
-
Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity
por: Szabó, Zoltán, et al.
Publicado: (2021) -
Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
por: Gan, Lu, et al.
Publicado: (2022) -
Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues
por: Russo, Ethan B.
Publicado: (2016) -
Oleoylethanolamide as a New Therapeutic Strategy to Alleviate Doxorubicin-Induced Cardiotoxicity
por: Qin, Yeyu, et al.
Publicado: (2022) -
Biomarker panel for early screening of trastuzumab -induced cardiotoxicity among breast cancer patients in west virginia
por: Pillai, Sneha S., et al.
Publicado: (2022)